GP2 peptide / GM-CSF vaccine

Drug Overview

The GP2 peptide / GM-CSF vaccine is an investigational “off-the-shelf” cancer vaccine designed to prevent the recurrence of HER2-positive breast cancer. It belongs to a class of immunotherapies known as peptide vaccines, which aim to program the patient’s own immune system to recognize and eliminate residual cancer cells that may remain in the body after surgery.

Developed by Greenwich LifeSciences, the vaccine consists of two primary components: the GP2 peptide, a small fragment of the HER2/neu protein, and GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor), an “adjuvant” that acts as a chemical alarm to attract immune cells to the injection site.

• Generic Name: GP2 peptide / GM-CSF vaccine.
• Target: HER2/neu protein (Human Epidermal Growth Factor Receptor 2).
• HLA Type: HLA-A*02 positive (most commonly studied).
• Drug Class: Cancer Vaccine / Active Immunotherapy.
• Route of Administration: Intradermal (into the skin) injection.
• FDA Approval Status: Investigational. As of March 2026, the vaccine is not FDA-approved. It is currently in a pivotal Phase III clinical trial (FLAMINGO-01) to confirm its efficacy in preventing breast cancer recurrence.

What Is It and How Does It Work? (Mechanism of Action)

The GP2 vaccine works through a “Search and Destroy” strategy that specifically targets the HER2 protein found on certain breast cancer cells.

The GP2 Peptide and GM-CSF Adjuvant

The GP2 peptide is a 9-amino acid fragment derived from the transmembrane domain of the HER2 protein. While many HER2 drugs (like Herceptin) use antibodies to block the protein, this vaccine uses the peptide to train T-cells to recognize the protein. GM-CSF is added to the injection to “recruit” Dendritic Cells—the teachers of the immune system—to the site so they can pick up the GP2 fragment.

Molecular Level Mechanisms

1. Dendritic Cell Uptake: Once injected into the skin, Dendritic Cells absorb the GP2 peptide and the GM-CSF.
2. Antigen Presentation: The Dendritic Cells travel to the lymph nodes, where they display the GP2 peptide on their surface using HLA molecules.
3. T-cell Activation: The “Killer T-cells” (CD8+ lymphocytes) in the lymph node recognize the GP2 peptide as a foreign invader and become “primed.”
4. Immune Surveillance: These newly trained T-cells circulate through the body. If they encounter a residual breast cancer cell expressing HER2, they bind to it and release toxic enzymes to kill the cell.
5. Immunological Memory: The body maintains a population of “Memory T-cells” that remain vigilant for years, potentially preventing the cancer from ever returning.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for the GP2 vaccine.

It is strictly available through participation in clinical trials (such as NCT05232916). It is primarily being studied for:

• HER2-Positive Breast Cancer (Adjuvant Setting): For patients who have completed surgery and standard-of-care treatments (like Herceptin or Kadcyla) but are at high risk of recurrence.
• HER2-Low Breast Cancer: Investigated for patients whose tumors have low levels of HER2 expression that might not qualify for traditional antibody therapies.

Dosage and Administration Protocols

In current Phase III research protocols, the GP2 vaccine is administered as a series of injections over a long period to ensure the immune system remains “reminded” of the target.

Clinical Efficacy and Research Results

The development of the GP2 vaccine has been marked by a particularly high success rate in specific subgroups of patients.

• 0% Recurrence Rate: In a pivotal Phase II clinical trial, HER2-positive patients who were HLA-A*02 positive and received the full GP2 vaccine series showed a 0.0% recurrence rate after five years of follow-up, compared to roughly 11% in the control group.
• Robust T-cell Response: Blood tests in clinical trials (Skin Delayed-Type Hypersensitivity tests) confirmed that 100% of vaccinated patients developed a strong immune response to the GP2 peptide.
• The FLAMINGO-01 Trial: The current 2026 Phase III trial aims to replicate these results in a much larger group of patients globally to seek FDA approval.

Safety Profile and Side Effects

The GP2 vaccine is considered extremely safe compared to traditional chemotherapy because it specifically targets the immune system rather than killing all fast-growing cells.

Common Side Effects:

• Injection Site Reactions (90%+): Redness, swelling, and itching where the shot was given.
• Flu-like Symptoms: Mild fever, chills, and body aches for 24–48 hours after the injection.
• Fatigue: A temporary sense of tiredness.
• Headache.

Serious Risks:

• None Identified to Date: In clinical trials conducted thus far, no serious adverse events (SAEs) or “dose-limiting toxicities” have been reported. The vaccine does not appear to cause the heart problems sometimes associated with other HER2 drugs.

Research Areas

In Stem Cell and Regenerative Medicine, the GP2 vaccine is being studied in the context of “Immune Niche Preservation.” Researchers are investigating whether maintaining a “primed” immune environment through vaccination can protect the patient’s own healthy stem cells in the bone marrow from being crowded out by metastasizing cancer cells. This research is vital for understanding how the body can “regenerate” a healthy immune system while simultaneously fighting off residual microscopic disease.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• HLA Typing: This is critical. Current research suggests the vaccine is most effective in patients who are HLA-A*02 positive.
• HER2 Status Confirmation: Confirmation that the original tumor was HER2 1+, 2+, or 3+ via IHC or FISH testing.

Precautions:

• Pregnancy: The vaccine should not be administered during pregnancy, as the effects on the developing fetus are unknown.
• Immunosuppressants: Patients should avoid high-dose steroids or other drugs that suppress the immune system while receiving the vaccine, as these can block the vaccine’s effectiveness.

“Do’s and Don’ts”:

• DO expect a red, raised bump at the injection site; this “positive skin test” is a sign that your immune system is learning.
• DO stay hydrated and take over-the-counter pain relief (like acetaminophen) if you experience a mild fever after the shot.
• DON’T skip the booster shots; the immune system requires “reminders” to maintain its protective memory.
• DON’T ignore any severe allergic reactions (difficulty breathing, hives), though these are extremely rare.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. The GP2 peptide / GM-CSF vaccine is an investigational agent and is not currently approved by the US FDA. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding your diagnosis and eligibility for clinical research.